Leerink maintains Outperform on BridgeBio Oncology Thera, cuts PT to $27
Leerink Partners maintained BridgeBio Oncology Thera at Outperform and cut its price target to $27.00 per share from $39.00, according to a ratings-action report.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.